信邦制药: 关于2025年半年度利润分配预案的公告

Core Viewpoint - Guizhou Xibang Pharmaceutical Co., Ltd. has proposed a profit distribution plan for the first half of 2025, which will be submitted for approval at the company's first extraordinary general meeting of shareholders in 2025 [1][2]. Group 1: Approval Process - The board of directors approved the profit distribution plan with 8 votes in favor, 0 against, and 0 abstentions during the eighth meeting of the ninth board on August 28, 2025 [1]. - The supervisory board also approved the profit distribution plan with 3 votes in favor, 0 against, and 0 abstentions, confirming its compliance with relevant regulations and its benefit to the company's normal operations and healthy development [1][2]. Group 2: Profit Distribution Plan Details - The company achieved a net profit of approximately 142.45 million yuan for the year, with a net profit attributable to shareholders of approximately 107.20 million yuan [2]. - The profit distribution plan proposes a cash dividend of 0.30 yuan per 10 shares (including tax), with a total expected cash dividend of approximately 56.89 million yuan [2]. - The total share capital after the repurchase of 47,445,540 shares is 1,896,406,328 shares, which serves as the basis for the distribution [2]. Group 3: Legality of Cash Dividend Plan - The cash dividend plan is deemed legal, compliant, and reasonable, adhering to the Company Law, Securities Law, and relevant guidelines [3]. - The plan is designed to ensure the company's normal operations and long-term development while providing continuous returns to investors [2][3].